Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2009-07-20
2010-12-28
Lewis, Patrick T (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S050000, C514S051000
Reexamination Certificate
active
07858594
ABSTRACT:
Physical forms of beta-L-2′-deoxythymidine are disclosed that can be characterized by physical appearance, purity levels, Infra-Red and Raman spectroscopy, X-ray powder diffraction patterns, thermal properties, and methods of manufacture. These forms of beta-L-2′-deoxythymidine can be used in the manufacture of other forms of beta-L-2′-deoxythymidine, or in pharmaceutical compositions. Particularly preferred uses are in the treatment of hepatitis B.
REFERENCES:
patent: 4916122 (1990-04-01), Chu
patent: 4957924 (1990-09-01), Beauchamp
patent: 5149794 (1992-09-01), Yatvin
patent: 5190926 (1993-03-01), Chu
patent: 5194654 (1993-03-01), Hostetler
patent: 5220003 (1993-06-01), Jung
patent: 5223263 (1993-06-01), Hostetler
patent: 5256641 (1993-10-01), Yatvin
patent: 5411947 (1995-05-01), Hostetler et al.
patent: 5463092 (1995-10-01), Hostetler et al.
patent: 5539116 (1996-07-01), Liotta et al.
patent: 5543389 (1996-08-01), Yatvin et al.
patent: 5543390 (1996-08-01), Yatvin et al.
patent: 5543391 (1996-08-01), Yatvin et al.
patent: 5554728 (1996-09-01), Basava et al.
patent: 5559101 (1996-09-01), Weis et al.
patent: 5565438 (1996-10-01), Chu
patent: 5567688 (1996-10-01), Chu
patent: 5587362 (1996-12-01), Chu
patent: 5939402 (1999-08-01), Weis et al.
patent: 5990093 (1999-11-01), Schinazi et al.
patent: 6025335 (2000-02-01), Weis et al.
patent: 6194391 (2001-02-01), Schinazi et al.
patent: 6245749 (2001-06-01), Schinazi et al.
patent: 6297222 (2001-10-01), von Borstel et al.
patent: 6395716 (2002-05-01), Gosselin et al.
patent: 6444652 (2002-09-01), Gosselin et al.
patent: 6462174 (2002-10-01), Roberts
patent: 6566344 (2003-05-01), Gosselin et al.
patent: 6569837 (2003-05-01), Gosselin et al.
patent: 6723728 (2004-04-01), Hu et al.
patent: 2206878 (1997-03-01), None
patent: 0 350 287 (1990-01-01), None
patent: 0 352 248 (1990-01-01), None
patent: 0 494 119 (1992-07-01), None
patent: 0 355 131 (1996-09-01), None
patent: 875971 (1961-08-01), None
patent: 6-293645 (1994-10-01), None
patent: WO 89/02733 (1989-04-01), None
patent: WO 89/03838 (1989-05-01), None
patent: WO 90/00555 (1990-01-01), None
patent: WO 91/16920 (1991-11-01), None
patent: WO 91/18914 (1991-12-01), None
patent: WO 91/19721 (1991-12-01), None
patent: WO 92/08727 (1992-05-01), None
patent: WO 92/15308 (1992-09-01), None
patent: WO 92/18517 (1992-10-01), None
patent: WO 93/00910 (1993-01-01), None
patent: WO 94/01138 (1994-01-01), None
patent: WO 94/20523 (1994-09-01), None
patent: WO 94/26273 (1994-11-01), None
patent: WO 95/07086 (1995-03-01), None
patent: WO 96/11204 (1996-04-01), None
patent: WO 96/13512 (1996-05-01), None
patent: WO 96/15132 (1996-05-01), None
patent: WO 96/40164 (1996-12-01), None
patent: WO 99/45935 (1999-09-01), None
patent: WO 00/09531 (2000-02-01), None
Saneyoshi et al., “Synthetic Nucleosides and Nucleotides. XIII. Stannic Chloride Catalyzed Ribosylation of Several 6-Substituted Purines,” Chemical and Pharmaceutical Bulletin, 27:2518-2521 (Jan. 1, 1979).
Schinazi, R.F., et al., “Effect of Combinations of Acylovir with Vidarabine or its 5′-Monophosphate on Herpes Simplex Viruses in Cell Culture and in Mice,” Antimicrobial Agents and Chemotherapy, 22(3):499-507 (Sep. 1982).
Schinazi, R.F., et al., “Selective Inhibition of Human Immunodeficiency Viruses by Racemates and Enantiomers of cis-5-Fluoro-1-[2-(Hydroxymethyl)-1,3-Oxathiolane-5-yl] Cytosine,” Antimicrobial Agents and Chemotherapy, 36 (11):2423-2431 (Nov. 1992).
Shuto, S., et al., “A facile one-step synthesis of 5′-phosphatidylnucleosides by an enzymatic two-phase reaction,” Tetrahedron Letters, 28(2): 199-202 (1987).
Soderlund, J.C.F., “Mitochondrial verus cytosolic activities of deoxyribonucleoside salvage enzymes,” in Purine and Pyrimidine Metabolism in Man VIII, A. Shota & M. Taylor (Eds.), Plenum Press, New York, 1995, pp. 201-204.
Spadari, S., et al., “L-Thymidine is Phosphorylated by Herpes Simplex Type 1 Thymidine Kinase and Inhibits Viral Growth,” J. Med. Chem., 35(22):4214-4220 (1992).
Tyrsted et al., “Inhibition of the Synthesis of 5-Phosphoribosyl-I-Pyrophosphate by 3′-Deoxy-adenosine and Structurally Related Nucleoside Analogs,” Biochimica et Biophysica Acta, 155(2):619-622 (Feb. 26, 1968).
Verri, A., et al., “Lack of enantiospecificity of human 2′-deoxycytidine kinase: relevance for the activation of Beta-L-deoxycytidine analogs as antineoplastic and anti viral agents,” Molecular Pharmacology, 51(1):132-138 (Nov. 1997).
Verri, A., et al., “Relaxed Enantioselectivity of Human Mitochondrial Thymidine Kinase and Chemotherapeutic Uses of L-Nucleoside Analogues,” Biochem. J.., 328(1):317-320 (Nov. 1997).
Voet et al., “Absorption Spectra of Nucleotides, Polynucleotides, and Nucleic Acids in the Far Ultraviolet,” Biopolymers, 155 (2):193-208 (Jan. 1, 1963).
Von Janta-Lipinski, M., Newly Synthesized L-Enantiometers of 3′-Fluoro-Modified Beta-2′-Deoxyribonucleoside 5′Triphosphates Inhibit Hepatitis B DNA Polymerase but not the Five Cellular DNA Polymerases α, β, γ, δ, ε Nor HIV-1 Reverse Transscriptase, J. Medicinal Chemistry, 41 (12):2040-2046 (May 21, 1998).
Wang et al.m “Recovery of Liver Sinusoidal Endothelial Cell Function over Time after Hypothermic Preservation in Rat Orthotopic Liver Transplantation, ”Hepatology (AASLD Abstracts—Abstract No. 1219), 24(4, Pt 2): 431A (Jan. 1, 1996).
Zedeck, M.S., et al., “Inhibition of the steroid-induced synthesis of D5-3-ketosteroid isomerase in Pseudomonas testosterone by a new purine deoxyribonucleoside analog: 6-chloro-8-aza-9-cyclopentylpuring,” Mol. PHarmacol., 3 (4):386-395 (1967).
Zhang et al., “Removal of Silyl Protecting Groups From Hydroxyl Functions with Ammonium Fluoride in Methanol,” Tetrahedron Letters, 33(9): 1177-1180 (Jan. 1, 1992).
Zhu, Y.L., et al., “Inhibition of Replication of Hepatitis B Virus by Cytallene In Vitro,” Antimocrobial Agents and Chemotherapy, 41(8): 1755-1760 (Aug. 1997).
Zhu, Y.L., et al., “Anti-Hepatitis B Virus Activity and Metabolism of 2′,3′-dideoxy-2′,3′-didehydro-beta-L-(-)-S-Fluorocytidine,” Antimicrobial Agents and Chemotherapy 42(7):1805-1810 (Jul. 1998).
Zhu, C., et al., “Incorporation of Nucleoside Analogs into Nuclear or Mitochondrial DNA is Determined by the Intracellular Phosphorylation Site,” J Biol Chem, 275(35):26727-26731 (2000).
Bridges, E.G. et al., “Characterization of a dCTP Transport Activity Reconstituted from Human Mitochondria,” J. Biol. Chem., 274(8):4620-4625 (Feb. 1999).
Amer, E.S.J., et al., “Mammalian Deoxyribonicleoside Kinases,” Pharm. Ther., 67(2), 155-186 (1995).
Berk, A.J., et al., “A Genetically Distinct Tymidine Kinase in Mammalian Mitochondria,” J. Biol Chem, 248(8): 2722-2729 (1973).
Bestwick, R.K., et al., “Selective Expansion of Mitochondrial Nucleoside Triphosphate Pools in Antimetabolite-treated HeLa Cells,” J. Biol. Chem., 257(16):9300-9304 (1982).
Bloch, A., et al., “The Role of the 5′-Hydroxyl Group of Adenosine in Determining Substrate Specificity for Adenosine Deaminase,” J. Med. Chem., 10(5):908-12 (Sep. 1967).
Bridges, E.G., et al., “Identification of a novel mitochondrial dNTP carrier and its interaction with anti-HIV nucleoside analogs,” Proc. Am. Assoc. Cancer Res., 38:414 (Mar. 1997).
Bridges, E.G. et al., “Inhibition of Mammalian DNA Polymerase-Associated 3′ to 5′ Exonuclease Activity by 5′Monophosphates of 3′-Azido-3′-Deoxythymine and 3′-Amino-3′-Deoxythymidine,” Biochemical Pharmacology, 45(8): 1571-1576 (1993).
Bryant, M.L, et al., “Antiviral L-Nucleosides Specific for Hepatitis B Virus Infection,” Antimicrobial Agents and Chemotherapy, 45(1):229-235 (Jan. 2001).
Chang, C.N.,
Jonaitis David
Storer Richard
Dilworth & Barrese LLP
Lewis Patrick T
Novartis Pharma AG
Pokalsky, Esq. Ann R.
LandOfFree
Crystalline and amorphous forms of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Crystalline and amorphous forms of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Crystalline and amorphous forms of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4183944